Navigation Links
Onyx Pharmaceuticals Announces Third Quarter 2010 Financial Results Teleconference and Webcast
Date:10/26/2010

EMERYVILLE, Calif., Oct. 26 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that it will host a webcast and teleconference with management to provide a general business overview, as well as to discuss third quarter 2010 financial results, on Wednesday, November 3, 2010, at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).  Financial results for the third quarter ended September 30, 2010 will be released earlier that day.

Interested parties may access a live webcast of the presentation on the company's website at: http://www.onyx-pharm.com/view.cfm/32/Event-Calendar or by dialing 847-413-3362 and using the passcode 28272610#.  A replay of the presentation will be available on the Onyx website or by dialing 630-652-3042 and using the passcode 28272610# approximately one hour after the teleconference concludes.  The replay will be available through November 17, 2010. 

About Onyx Pharmaceuticals, Inc.

Onyx Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of people with cancer. The company, in collaboration with Bayer HealthCare Pharmaceuticals Inc., is developing and marketing Nexavar® (sorafenib) tablets, a small molecule drug that is currently approved for the treatment of liver cancer and advanced kidney cancer. Additionally, Nexavar is being investigated in several ongoing trials in a variety of tumor types. Beyond Nexavar, Onyx has established a development pipeline of anticancer compounds at various stages of clinical testing, including carfilzomib, a proteasome inhibitor, that is currently being evaluated in multiple clinical trials for the treatment of patients with relapsed or relapsed/refractory multiple myeloma and solid tumors. ONX 0801, an alpha-folate receptor targeted inhibitor of thymidylate synthase, and ONX 0912, an oral proteasome inhibitor, are currently in Phase 1 testing. For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Nexavar® (sorafenib) tablets is a registered trademark of Bayer HealthCare Pharmaceuticals.


'/>"/>
SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Strativa Pharmaceuticals Signs Agreement With Swedish Orphan Biovitrum Regarding Nascobal®
2. Keryx Biopharmaceuticals Announces Completion of Patient Enrollment In Zerenex Phase 3 Short-Term Study
3. Celtic Therapeutics and Resolvyx Pharmaceuticals Announce an Alliance in Ophthalmology
4. Savient Pharmaceuticals to Hold Conference Call on October 26, 2010 at 8:30 a.m. Eastern Time
5. Savient Pharmaceuticals Provides Update on Strategic Alternatives Process
6. Optimer Pharmaceuticals Announces Combined Data From Fidaxomicin Phase 3 Trials for the Treatment of Clostridium difficile Infection (CDI) Presented at IDSA
7. Lotus Pharmaceuticals Preparing to Apply for National Exchange Listing
8. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
9. Transdel Pharmaceuticals Appoints John N. Bonfiglio, Ph.D. as Chief Executive Officer and President
10. MAP Pharmaceuticals Appoints Thomas P. McCracken as Vice President, Intellectual Property
11. Endo Pharmaceuticals to Announce Third Quarter 2010 Financial Results on November 1, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2017)... LOVELAND, Colo. , July 26, 2017 ... Tristan Guttridge and the Bimini SharkLab to custom design the ... diagnostic images of sharks in their native habitat. In ... for Discovery Channel,s Shark Week, Dr. Guttridge approached ... to take pregnancy diagnosis directly to hammerhead sharks underwater. ...
(Date:7/26/2017)... , July 26, 2017 Sancilio Pharmaceuticals ... of our clinical trial evaluating Altemia TM , an ... (SCA) and Sickle Cell Disease (SCD). The SCOT Trial, ... the efficacy and safety of Altemia TM in ... conducted under US IND 125274. ...
(Date:7/25/2017)... CAMBRIDGE, Massachusetts , July 25, 2017 /PRNewswire/ ... drugs to treat rare nervous system diseases, has concluded a ... and market the drug SOM0226 against transthyretin amyloidosis (ATTR). Before ... promising results in a Phase 2 study conducted in ... in the United States ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... August 17, 2017 , ... ... Wednesday, August 16, to community partners. The newly renovated ER was designed with ... for minor emergencies, eight semi-private rooms to deliver patient results, improve efficiencies and ...
(Date:8/17/2017)... ... August 17, 2017 , ... ... to Healing Through Forgiveness ($15.99, paperback, 9781498497626; $7.99, eBook, 9781498497633) focuses on ... inner healing of memories and achieve forgiveness, through a progressive journey toward healing. ...
(Date:8/17/2017)... ... , ... Advice Media, the industry leader in digital marketing for medical practices, has been recognized ... included in the Inc. 5000 for the second time in two years. Shawn Miele, Chief ... 5000 rankings for the second year in a row. It’s extremely difficult to make this ...
(Date:8/16/2017)... ... ... Summer days spent with family are priceless. Since August is Family Fun Month, ... season of sunshine. Add trying something new to this summer’s bucket list. Whether it’s ... fun. , Try Something New , Choose an activity the whole ...
(Date:8/16/2017)... ... ... Ten outstanding teachers in the Greater Houston area will be named one ... by a Houston Texans player, two tickets to a Texans game, and other prizes. ... texanschecking.com/stars to nominate their favorite teacher with an essay of no more than 500 ...
Breaking Medicine News(10 mins):